Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
132.06
+1.13 (0.86%)
Aug 7, 2025, 4:00 PM - Market closed
Blueprint Medicines Revenue
Abbott Laboratories had revenue of $11.14B in the quarter ending June 30, 2025, with 7.37% growth. This brings the company's revenue in the last twelve months to $43.11B, up 5.85% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$43.11B
Revenue Growth
+5.85%
P/S Ratio
5.33
Revenue / Employee
$378,149
Employees
114,000
Market Cap
229.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ABT News
- 11 days ago - Best Dividend Aristocrats For August 2025 - Seeking Alpha
- 15 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 16 days ago - Best Dividend Kings: July 2025 - Seeking Alpha
- 20 days ago - These Analysts Revise Their Forecasts On Abbott Following Q2 Results - Benzinga
- 20 days ago - Abbott Laboratories: What's Behind The Q2 Earnings Slump? - Seeking Alpha
- 21 days ago - Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction' - CNBC
- 21 days ago - Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga